MHRA (UK)
OTHER
UPDATE: Class 4 Medicines Defect Notification: Relonchem Limited, Gabapentin Relonchem 50mg/ml Oral Solution, EL(26)A/31
Published: 7/7/2026Detected: 6/30/2026
Summary preview
Triggers a MHRA defect notification for a gabapentin oral solution due to customer-reported particles observed in some bottles, indicating a potential quality defect and consumer safety risk.
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountneurology
manufacturing
quality
safety
labeling
#MHRA
#defect notification
#Class 4
#gabapentin
#oral solution
Official Source Document Source Verified
Access the original document directly from MHRA.
More from MHRA (UK)
- Class 4 Medicines Defect Notification: Star Pharmaceuticals Ltd, Enalapril maleate/ Hydrochlorothiazide 20 mg/12.5 mg Tablets, EL(26)A/4811/12/2026
- Field Safety Notices from 02 to 06 November2026.11/10/2026
- Class 4 Medicines Defect Notification: Sandoz Limited, Co-Amoxiclav powder for oral suspension 250/62.5 mg/5mL, EL(26)A/4611/5/2026
- Class 3 Medicines Recall: Aspire Pharma Limited, Tropicamide 1% Eye Drops, solution in single dose containers 20 x 0.5ml , EL(26)A/4711/5/2026
- Field Safety Notices: 26 to 30 October 202611/4/2026